Neurochemical Research

, Volume 36, Issue 11, pp 1947–1954 | Cite as

Stability Analysis of Vascular Endothelial Growth Factor in Cerebrospinal Fluid

  • Jun Yang
  • Stephen M. Dombrowski
  • Abhishek Deshpande
  • Natalie Krajcir
  • Serge El-Khoury
  • Chandra Krishnan
  • Mark G. Luciano
Original Paper

Abstract

Vascular endothelial growth factor (VEGF) is a promising biological marker and prognostic indicator in many neurological diseases. Although VEGF concentrations in plasma and cerebrospinal fluid (CSF) are increasingly reported, CSF-VEGF stability pre- and during-assay procedures is seldom evaluated. In the current study, we investigated VEGF variability and stability in CSF related to sample preparation, storage, and routine experimental procedures. Results showed that contaminant cell breakdown or aggregation can occur gradually before sample processing. However, after the removal of contaminant cell components, CSF-VEGF levels did not show significant changes in samples incubated at room temperature for 5 h, thawed/refrozen for 6 cycles. Samples preserved at −80°C for up to 7 years continued to show measurable levels. Since some cellular components such as platelets contain a large amount of releasable VEGF, we conclude that CSF samples should be processed as soon as possible to carefully remove all cellular components and prevent possible consequent release of VEGF into CSF. After centrifugation to remove cellular contents, VEGF in CSF was relatively stable during routine experimental procedures and storage.

Keywords

Cell count Centrifugation Temperature Time Preservation 

References

  1. 1.
    Ferrara N (2010) Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 16:1107–1111PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med (JMM) 77:527–543CrossRefGoogle Scholar
  3. 3.
    Ferrara N (1996) Vascular endothelial growth factor. Eur J Cancer 32A:2413–2422PubMedCrossRefGoogle Scholar
  4. 4.
    Dombrowski SM, Deshpande A, Dingwall C et al (2008) Chronic hydrocephalus-induced hypoxia: increased expression of VEGFR-2+ and blood vessel density in hippocampus. Neuroscience 152:346–359PubMedCrossRefGoogle Scholar
  5. 5.
    Yang J, Dombrowski SM, Deshpande A et al (2010) VEGF/VEGFR-2 changes in frontal cortex, choroid plexus, and CSF after chronic obstructive hydrocephalus. J Neurol Sci 296:39–46PubMedCrossRefGoogle Scholar
  6. 6.
    Deshpande A, Dombrowski SM, Leichliter A et al (2009) Dissociation between vascular endothelial growth factor receptor-2 and blood vessel density in the caudate nucleus after chronic hydrocephalus. J Cereb Blood Flow Metab 29:1806–1815PubMedCrossRefGoogle Scholar
  7. 7.
    Moreau C, Devos D, Brunaud-Danel V et al (2006) Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry 77:255–257PubMedCrossRefGoogle Scholar
  8. 8.
    Hu WT, Chen-Plotkin A, Arnold SE et al (2010) Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment. Acta Neuropathol 119:669–678PubMedCrossRefGoogle Scholar
  9. 9.
    Tarnaris A, Toma AK, Chapman MD et al (2009) The longitudinal profile of CSF markers during external lumbar drainage. J Neurol Neurosurg Psychiatry 80:1130–1133PubMedCrossRefGoogle Scholar
  10. 10.
    Hormbrey E, Gillespie P, Turner K et al (2002) A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastas 19:651–663CrossRefGoogle Scholar
  11. 11.
    Provencio JJ, Kivisakk P, Tucky BH et al (2005) Comparison of ventricular and lumbar cerebrospinal fluid T cells in non-inflammatory neurological disorder (NIND) patients. J Neuroimmunol 163:179–184PubMedCrossRefGoogle Scholar
  12. 12.
    Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964PubMedCrossRefGoogle Scholar
  13. 13.
    Maloney JP, Silliman CC, Ambruso DR et al (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275:H1054–H1061PubMedGoogle Scholar
  14. 14.
    Gunsilius E, Petzer A, Stockhammer G et al (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58:169–174PubMedCrossRefGoogle Scholar
  15. 15.
    Mohle R, Green D, Moore MA et al (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94:663–668PubMedCrossRefGoogle Scholar
  16. 16.
    Wartiovaara U, Salven P, Mikkola H et al (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80:171–175PubMedGoogle Scholar
  17. 17.
    O’byrne KJ, Dobbs N, Propper D et al (1999) Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 353:1494–1495PubMedCrossRefGoogle Scholar
  18. 18.
    Harris AL (1998) Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res 152:341–352PubMedGoogle Scholar
  19. 19.
    Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90:3167–3172PubMedGoogle Scholar
  20. 20.
    Freeman MR, Schneck FX, Gagnon ML et al (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55:4140–4145PubMedGoogle Scholar
  21. 21.
    Berse B, Brown LF, Van De Water L et al (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211–220PubMedGoogle Scholar
  22. 22.
    Aursnes I, Vikholm V (1984) On a possible interaction between ADP and mechanical stimulation in platelet activation. Thromb Haemost 51:54–56PubMedGoogle Scholar
  23. 23.
    Webb NJ, Bottomley MJ, Watson CJ et al (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94:395–404Google Scholar
  24. 24.
    Reid TJ, Larussa VF, Esteban G et al (1999) Cooling and freezing damage platelet membrane integrity. Cryobiology 38:209–224PubMedCrossRefGoogle Scholar
  25. 25.
    Sanz C, Pereira A, Faundez AI et al (1997) Prolonged holding of whole blood at 22 degrees C does not increase activation in platelet concentrates. Vox Sang 72:225–228PubMedCrossRefGoogle Scholar
  26. 26.
    Jacobsen J, Rasmuson T, Grankvist K et al (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343–347PubMedCrossRefGoogle Scholar
  27. 27.
    Wynendaele W, Derua R, Hoylaerts MF et al (1999) Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 10:965–971PubMedCrossRefGoogle Scholar
  28. 28.
    Salven P, Ruotsalainen T, Mattson K et al (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79:144–146PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jun Yang
    • 1
  • Stephen M. Dombrowski
    • 1
  • Abhishek Deshpande
    • 1
  • Natalie Krajcir
    • 1
  • Serge El-Khoury
    • 1
  • Chandra Krishnan
    • 1
  • Mark G. Luciano
    • 1
  1. 1.Department of Neurological Surgery, Section of Pediatric and Congenital Neurological Surgery, CSF Physiology Laboratory, Neurological InstituteCleveland ClinicClevelandUSA

Personalised recommendations